p53 in endometrial cancer and its putative precursors: Evidence for diverse pathways of tumorigenesis

Mark E. Sherman, Martin E. Bur, Robert J Kurman

Research output: Contribution to journalArticle

Abstract

To elucidate the role of p53 abnormalities in endometrial tumorigenesis, a diverse group of endometrial neoplasms and their putative precursors, atypical endometrial hyperplasia, and endometrial intraepithelial carcinoma (EIC) were studied using a conventional immunohistochemical technique. Immunostaining for p53 protein was detected in 24 (86%) of 28 serous carcinomas compared with nine (20%) of 45 endometrioid carcinomas (P <.001). Immunoreactivity was also detected in two (100%) of two clear cell carcinomas, five (83%) of six mixed endometrioid/serous carcinomas, and seven (70%) of 10 malignant mixed mesodermal tumors. Benign endometrial tissue and 12 examples of atypical endometrial hyperplasia were nonreactive. In 27 (79%) of 34 tumors containing EIC, both the tumor and EIC were immunoreactive for p53, whereas in 7 (21 %) both were negative. Immunostaining for p53 highlighted small foci of EIC and showed the extent and distribution of the lesions. The strong association and similar p53 immunostaining pattern of EIC and serous carcinoma support the hypothesis that serous carcinomas develop from endometrial surface epithelium that demonstrates abnormal p53 protein expression in conjunction with transformation to EIC. Mutation of p53 seems unrelated to the development of endometrioid carcinoma from atypical endometrial hyperplasia but may be related to dedifferentiation in some of these neoplasms.

Original languageEnglish (US)
Pages (from-to)1268-1274
Number of pages7
JournalHuman Pathology
Volume26
Issue number11
DOIs
StatePublished - 1995

Fingerprint

Endometrial Neoplasms
Carcinoma in Situ
Carcinogenesis
Endometrioid Carcinoma
Endometrial Hyperplasia
Carcinoma
Malignant Mixed Tumor
Neoplasms
Proteins
Epithelium
Mutation

Keywords

  • cancer precursor
  • endometrial carcinoma
  • endometrial hyperplasia
  • endometrial intraepithelial carcinoma
  • malignant mixed mesodermal tumors
  • p53
  • serous carcinoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

p53 in endometrial cancer and its putative precursors : Evidence for diverse pathways of tumorigenesis. / Sherman, Mark E.; Bur, Martin E.; Kurman, Robert J.

In: Human Pathology, Vol. 26, No. 11, 1995, p. 1268-1274.

Research output: Contribution to journalArticle

@article{83ccf294acdb4b06a7e271749bb018cc,
title = "p53 in endometrial cancer and its putative precursors: Evidence for diverse pathways of tumorigenesis",
abstract = "To elucidate the role of p53 abnormalities in endometrial tumorigenesis, a diverse group of endometrial neoplasms and their putative precursors, atypical endometrial hyperplasia, and endometrial intraepithelial carcinoma (EIC) were studied using a conventional immunohistochemical technique. Immunostaining for p53 protein was detected in 24 (86{\%}) of 28 serous carcinomas compared with nine (20{\%}) of 45 endometrioid carcinomas (P <.001). Immunoreactivity was also detected in two (100{\%}) of two clear cell carcinomas, five (83{\%}) of six mixed endometrioid/serous carcinomas, and seven (70{\%}) of 10 malignant mixed mesodermal tumors. Benign endometrial tissue and 12 examples of atypical endometrial hyperplasia were nonreactive. In 27 (79{\%}) of 34 tumors containing EIC, both the tumor and EIC were immunoreactive for p53, whereas in 7 (21 {\%}) both were negative. Immunostaining for p53 highlighted small foci of EIC and showed the extent and distribution of the lesions. The strong association and similar p53 immunostaining pattern of EIC and serous carcinoma support the hypothesis that serous carcinomas develop from endometrial surface epithelium that demonstrates abnormal p53 protein expression in conjunction with transformation to EIC. Mutation of p53 seems unrelated to the development of endometrioid carcinoma from atypical endometrial hyperplasia but may be related to dedifferentiation in some of these neoplasms.",
keywords = "cancer precursor, endometrial carcinoma, endometrial hyperplasia, endometrial intraepithelial carcinoma, malignant mixed mesodermal tumors, p53, serous carcinoma",
author = "Sherman, {Mark E.} and Bur, {Martin E.} and Kurman, {Robert J}",
year = "1995",
doi = "10.1016/0046-8177(95)90204-X",
language = "English (US)",
volume = "26",
pages = "1268--1274",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "11",

}

TY - JOUR

T1 - p53 in endometrial cancer and its putative precursors

T2 - Evidence for diverse pathways of tumorigenesis

AU - Sherman, Mark E.

AU - Bur, Martin E.

AU - Kurman, Robert J

PY - 1995

Y1 - 1995

N2 - To elucidate the role of p53 abnormalities in endometrial tumorigenesis, a diverse group of endometrial neoplasms and their putative precursors, atypical endometrial hyperplasia, and endometrial intraepithelial carcinoma (EIC) were studied using a conventional immunohistochemical technique. Immunostaining for p53 protein was detected in 24 (86%) of 28 serous carcinomas compared with nine (20%) of 45 endometrioid carcinomas (P <.001). Immunoreactivity was also detected in two (100%) of two clear cell carcinomas, five (83%) of six mixed endometrioid/serous carcinomas, and seven (70%) of 10 malignant mixed mesodermal tumors. Benign endometrial tissue and 12 examples of atypical endometrial hyperplasia were nonreactive. In 27 (79%) of 34 tumors containing EIC, both the tumor and EIC were immunoreactive for p53, whereas in 7 (21 %) both were negative. Immunostaining for p53 highlighted small foci of EIC and showed the extent and distribution of the lesions. The strong association and similar p53 immunostaining pattern of EIC and serous carcinoma support the hypothesis that serous carcinomas develop from endometrial surface epithelium that demonstrates abnormal p53 protein expression in conjunction with transformation to EIC. Mutation of p53 seems unrelated to the development of endometrioid carcinoma from atypical endometrial hyperplasia but may be related to dedifferentiation in some of these neoplasms.

AB - To elucidate the role of p53 abnormalities in endometrial tumorigenesis, a diverse group of endometrial neoplasms and their putative precursors, atypical endometrial hyperplasia, and endometrial intraepithelial carcinoma (EIC) were studied using a conventional immunohistochemical technique. Immunostaining for p53 protein was detected in 24 (86%) of 28 serous carcinomas compared with nine (20%) of 45 endometrioid carcinomas (P <.001). Immunoreactivity was also detected in two (100%) of two clear cell carcinomas, five (83%) of six mixed endometrioid/serous carcinomas, and seven (70%) of 10 malignant mixed mesodermal tumors. Benign endometrial tissue and 12 examples of atypical endometrial hyperplasia were nonreactive. In 27 (79%) of 34 tumors containing EIC, both the tumor and EIC were immunoreactive for p53, whereas in 7 (21 %) both were negative. Immunostaining for p53 highlighted small foci of EIC and showed the extent and distribution of the lesions. The strong association and similar p53 immunostaining pattern of EIC and serous carcinoma support the hypothesis that serous carcinomas develop from endometrial surface epithelium that demonstrates abnormal p53 protein expression in conjunction with transformation to EIC. Mutation of p53 seems unrelated to the development of endometrioid carcinoma from atypical endometrial hyperplasia but may be related to dedifferentiation in some of these neoplasms.

KW - cancer precursor

KW - endometrial carcinoma

KW - endometrial hyperplasia

KW - endometrial intraepithelial carcinoma

KW - malignant mixed mesodermal tumors

KW - p53

KW - serous carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0028887101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028887101&partnerID=8YFLogxK

U2 - 10.1016/0046-8177(95)90204-X

DO - 10.1016/0046-8177(95)90204-X

M3 - Article

C2 - 7590703

AN - SCOPUS:0028887101

VL - 26

SP - 1268

EP - 1274

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 11

ER -